Involvement of the p38 mitogen‐activated protein kinase cascade in hepatocellular carcinoma
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The mitogen‐activated protein kinase (MAPK) cascade is activated in response to various extracellular stimuli. The authors investigated the involvement of the p38 MAPK, a member of the MAPK superfamily, cascade in hepatoma cell lines and in human hepatocellular carcinoma (HCC) tissue specimens. METHODS: Constitutively active mutant of MAPK kinase 6 (MKK6), which is upstream of p38 MAPK, was transfected into the HepG2 and HuH7 human hepatoma cell lines. The constitutive active mutant was constructed by replacing Ser‐189 and Thr‐193 with Glu. The growth and death of mutant MKK6‐transfected hepatoma cells were analyzed by the WST‐1 and sub‐G1 assays. The surgically resected livers of 20 HCC patients were divided histologically into tumorous (T) and nontumorous (NT) lesions. p38 MAPK activity was analyzed using in vitro kinase assay and MKK6 activity was measured using Western blot analysis. RESULTS: Mutant MKK6 transfection increased p38 MAPK activity, cytochrome c release from the mitochondria to the cytosol, and caspase‐3 activity, accompanied by apoptosis. In contrast, SB203580, a p38 MAPK‐specific inhibitor, prevented MKK6‐induced apoptosis in hepatoma cell lines. In the T lesions of 20 HCC parients, p38 MAPK and MKK6 activities were significantly lower compared with NT lesions (P < 0.05). There was a significant positive correlation between p38 MAPK and MKK6 activity (r = 0.507, P < 0.05). Larger tumors (> 20 mm) exhibited lower levels of p38 MAPK and MKK6 activity than did smaller tumors (P < 0.05). CONCLUSIONS: These findings suggested that reduction of the p38 MAPK cascade may account, in part, for the resistance to apoptosis, leading to the unrestricted cell growth of human HCC. Cancer 2003;97:3017–26. © 2003 American Cancer Society. DOI 10.1002/cncr.11425
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Death Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866
Liu, Z.-G., Hsu, H., Goeddel, D. V., & Karin, M. (1996) · Cell · doi:10.1016/s0092-8674(00)81375-6 · Cited by 1,937
Induction of gadd45β by NF-κB downregulates pro-apoptotic JNK signalling
De Smaele, E., Zazzeroni, F., Papa, S., Nguyen, D. U., Jin, R., Jones, J., Cong, R., & Franzoso, G. (2001) · Nature · doi:10.1038/35104560 · Cited by 732
Cited by
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
“In support of this notion, p38 activity has been shown to be reduced in hepatocellular carcinomas in comparison to adjacent normal tissue, with tumour size inversely related to p38 activity (Iyoda et al., 2003).”
BackgroundSignal integration by JNK and p38 MAPK pathways in cancer development
Wagner, E. F., & Nebreda, Á. R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2694 · Cited by 2,586
p38MAPK: stress responses from molecular mechanisms to therapeutics
Coulthard, L. R., White, D. E., Jones, D. L., McDermott, M. F., & Burchill, S. A. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.06.005 · Cited by 691
Role of p38 MAP Kinase Signal Transduction in Solid Tumors
Koul, H. K., Pal, M., & Koul, S. (2013) · Genes & Cancer · doi:10.1177/1947601913507951 · Cited by 484
The complexity of mitogen-activated protein kinases (MAPKs) made simple
Krishna, M., & Narang, H. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8170-7 · Cited by 432
The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer
Yong, H.-Y., Koh, M.-S., & Moon, A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903321490 · Cited by 422
“p38 MAPK activity has been shown to induce apoptosis in hepatocellular carcinoma cell lines [92].”
Backgroundp38α suppresses normal and cancer cell proliferation by antagonizing the JNK–c-Jun pathway
Hui, L., Bakiri, L., Mairhorfer, A., Schweifer, N., Haslinger, C., Kenner, L., Komnenovic, V., Scheuch, H., Beug, H., & Wagner, E. F. (2007) · Nature Genetics · doi:10.1038/ng2033 · Cited by 352
p38 MAP kinase: a convergence point in cancer therapy
Olson, J. M., & Hallahan, A. R. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.01.007 · Cited by 335
The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC
Li, L., Zhao, G.-D., Shi, Z., Qi, L.-L., Zhou, L.-Y., & Fu, Z.-X. (2016) · Oncology Letters · doi:10.3892/ol.2016.5110 · Cited by 305
Mersch-Sundermann, V., Knasmüller, S., Wu, X.-J., Darroudi, F., & Kassie, F. (2004) · Toxicology · doi:10.1016/j.tox.2004.02.009 · Cited by 304
MEK and the inhibitors: from bench to bedside
Akinleye, A., Furqan, M., Mukhi, N., Ravella, P., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-27 · Cited by 291
Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence
Xu, Y., Li, N., Xiang, R., & Sun, P. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.04.004 · Cited by 282
The Mitochondrial Chaperone TRAP1 Promotes Neoplastic Growth by Inhibiting Succinate Dehydrogenase
Sciacovelli, M., Guzzo, G., Morello, V., Frezza, C., Zheng, L., Nannini, N., Calabrese, F., Laudiero, G., Esposito, F., Landriscina, M., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.019 · Cited by 264
NFκB1 is a suppressor of neutrophil-driven hepatocellular carcinoma
Wilson, C. L., Jurk, D., Fullard, N., Banks, P., Page, A., Luli, S., Elsharkawy, A. M., Gieling, R. G., Chakraborty, J. B., Fox, C., et al. (2015) · Nature Communications · doi:10.1038/ncomms7818 · Cited by 171
Thierbach, R., Schulz, T. J., Isken, F., Voigt, A., Mietzner, B., Drewes, G., von Kleist-Retzow, J.-C., Wiesner, R. J., Magnuson, M. A., Puccio, H., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi410 · Cited by 127
“The MAP kinase p38 in its phosphorylated state functions as a tumor suppressor protein (34–36), specifically in liver (37,38) and has been shown to suppress growth by inhibition of cyclin D1/cyclin-dependent kinase 4 (cdk4) complexes (34).”
BackgroundAntiprolactinoma Effect of Hordenine by Inhibiting MAPK Signaling Pathway Activation in Rats
Wang, X., Guo, R.-Z., Ma, L., Ding, Q.-Y., Meng, J.-H., Chen, Y.-G., & Wu, J.-H. (2020) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2020/3107290 · Cited by 6
“Many studies have reported that p38 MAPK participated in the development and progress of lung cancer [15], prostate cancer [16–18], bladder cancer [19, 20], breast cancer [21, 22], liver cancer [23], transformed follicular lymphoma [24, 25], and leukemia [26].”
Background
Metadata
- Authors
- Iyoda, K., Sasaki, Y., Horimoto, M., Toyama, T., Yakushijin, T., Sakakibara, M., Takehara, T., Fujimoto, J., Hori, M., Wands, J. R., & Hayashi, N.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2003-05-29
- Volume
- 97
- Issue
- 12
- Pages
- 3017-3026
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2169305606
- Cited by
- 148
- References
- 3
- FWCI
- 1.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.